

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: * HIV-1 IIIB Virus

Catalog Number: 398

Lot Number: 130359

С Release Category:

Provided: 1 mL of cell-free virus

TCID50= 1.46×10^5 /ml titered in PBMCs

p24= 211 ng/ml

Original Source: Human patient peripheral blood or bone marrow from patients with AIDS or related

diseases. Concentrated culture fluids of peripheral blood or bone marrow from several patients with AIDS or related diseases were used to establish a permanent productive

infection in a cloned permissive neo-plastic T cell line (H9).

Host Strain: H9. Also infects other human neo-plastic CD4⁺ T cells including CEM, U937, Molt 3, HeLa

CD4⁺ cells, and human peripheral blood lymphocytes.

Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20% at 0.5-1 \times Propagation:

106cells/mL for optimal growth. Split 1:2 or 1:4 every 2-3 days.

Sterility: Negative for bacteria, mycoplasma, and fungi.

Description: X4 (SI)

Special High capacity to replicate in human T cell lines. This virus appears to be well adapted for Characteristics: in vitro culture in T cells and replicates less well in fresh human macrophages. It utilizes

CXCR4 as a co-receptor. Host: H9. Also infects other human neo-plastic CD4+ T cells including CEM, U937, Molt 3, HeLa CD4+ cells, and human peripheral blood lymphocytes. Preparation: Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20% at $0.5-1 \times 10^6$ cells/ml for optimum growth. Split 1:2-1:4 every 2-3 days.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 08/10/2020 Page 1 of 2

AITERNATIVE NAME: HILV-111 B/H9

Recommended Storage:

Liquid nitrogen.

Contributor: Dr. Robert Gallo

References: M. Popovic, E. Read-Connole and R. C. Gallo. (1984). T4 positive human neoplastic cell

lines susceptible to and permissive for HTLV-IÌI. Lancet, 2(8417-8418), 1472-3. PUBMED

M. Popovic, M. G. Sarngadharan, E. Read and R. C. Gallo. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS

and pre-AIDS. Science, 224(4648), 497-500. PUBMED

L. Ratner, W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister and et al. (1985). Complete nucleotide

sequence of the AIDS virus, HTLV-III. Nature, 313(6000), 277-84. PUBMED

Acknowledgment for publications should read "The following reagent was obtained NOTE:

through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB Virus

from Dr. Robert Gallo (cat# 398)." Also include the references cited above in any

publications.

Scientists at for-profit institutions or who intend commercial use of this reagent

must contact the NCI Technology Transfer Center at the following email address: lauren.nguyen-antczak@nih.gov, before the reagent can be released.

Last Updated: August 10, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 08/10/2020 Page 2 of 2